Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21466567 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL24701941 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL25910675 | 0.90 | MAPT (0.54) | MAPTSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL25910632 | 0.90 | MAPT (0.54) | MAPTSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL21466530 | 0.88 | CTSL (0.55) | MAPTSMN1; SMN2KMT2AHDAC3HDAC4 | |
| SCHEMBL21466552 | 0.88 | CTSL (0.55) | MAPTSMN1; SMN2KMT2AHDAC3HDAC4 | |
| SCHEMBL24702172 | 0.88 | CTSL (0.55) | MAPTSMN1; SMN2KMT2AHDAC3HDAC4 | |
| SCHEMBL24787792 | 0.86 | HDAC3 (0.46) | MAPTSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL23127326 | 0.84 | ACE (0.54) | MAPTMEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL28551115 | 0.84 | ACE (0.54) | MAPTMEN1KMT2AHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| US-11713325-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2023-08-01 | — | — | US | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| EP-4101855-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2022-12-14 | — | — | EP | disclosed |
| US-20220242883-A1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2022-08-04 | — | — | US | disclosed |
| US-11339180-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2022-05-24 | — | — | US | disclosed |
| US-11332480-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2022-05-17 | — | — | US | disclosed |
| US-20210246146-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2021-08-12 | — | — | US | disclosed |
| US-20210070775-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | US | disclosed |
| US-10538535-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2020-01-21 | — | — | US | disclosed |
| US-10442820-B2 | — | — | 2019-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10538535-B2 | Antitumoral compounds | TP53, RB1, XPOT | MAPT 4761/4885SMN1; SMN2 2945/4885MEN1 553/4885 |
| US-11332480-B2 | Antitumoral compounds | TP53, RB1, XPOT | MAPT 4761/4885SMN1; SMN2 2945/4885MEN1 553/4885 |
| US-20210070775-A1 | Antitumoral Compounds | TP53, RB1, XPOT | MAPT 4761/4885SMN1; SMN2 2945/4885MEN1 553/4885 |
| US-10442820-B2 | — | RPS4X, RPS4Y1, XPOT | MAPT 4701/4885SMN1; SMN2 2686/4885MEN1 518/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | MAPT 34/4885SMN1; SMN2 3582/4885MEN1 2468/4885 |
| US-11713325-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | MAPT 4519/4885SMN1; SMN2 2847/4885MEN1 246/4885 |
| US-11339180-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | MAPT 4519/4885SMN1; SMN2 2847/4885MEN1 246/4885 |
| US-20210246146-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | MAPT 4519/4885SMN1; SMN2 2847/4885MEN1 246/4885 |
| US-20220242883-A1 | Antitumoral Compounds | TP53, TOP1, MCL1 | MAPT 4519/4885SMN1; SMN2 2847/4885MEN1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.